{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T11:08:28Z","timestamp":1794654508745,"version":"4.9.1"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2023-00356"],"award-info":[{"award-number":["2023-00356"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2022-01018"],"award-info":[{"award-number":["2022-01018"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2019-02397"],"award-info":[{"award-number":["2019-02397"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["ALFGBG-71320"],"award-info":[{"award-number":["ALFGBG-71320"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018707","name":"HORIZON EUROPE Reforming and enhancing the European Research and Innovation system","doi-asserted-by":"publisher","award":["101053962"],"award-info":[{"award-number":["101053962"]}],"id":[{"id":"10.13039\/100018707","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002565","name":"Alzheimer's Drug Discovery Foundation","doi-asserted-by":"publisher","award":["201809-2016862"],"award-info":[{"award-number":["201809-2016862"]}],"id":[{"id":"10.13039\/100002565","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","award":["ADSF-21-831376-C"],"award-info":[{"award-number":["ADSF-21-831376-C"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","award":["ADSF-21-831381-C"],"award-info":[{"award-number":["ADSF-21-831381-C"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","award":["ADSF-21-831377-C"],"award-info":[{"award-number":["ADSF-21-831377-C"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","award":["ADSF-24-1284328-C"],"award-info":[{"award-number":["ADSF-24-1284328-C"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","award":["ADSF-24-1284326-C"],"award-info":[{"award-number":["ADSF-24-1284326-C"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019599","name":"European Partnership on Metrology","doi-asserted-by":"publisher","award":["22HLT07"],"award-info":[{"award-number":["22HLT07"]}],"id":[{"id":"10.13039\/100019599","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003792","name":"Hj\u00e4rnfonden","doi-asserted-by":"publisher","award":["FO2022-0270"],"award-info":[{"award-number":["FO2022-0270"]}],"id":[{"id":"10.13039\/501100003792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018694","name":"HORIZON EUROPE Marie Sklodowska-Curie Actions","doi-asserted-by":"publisher","award":["860197"],"award-info":[{"award-number":["860197"]}],"id":[{"id":"10.13039\/100018694","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013278","name":"EU Joint Programme \u2013 Neurodegenerative Disease Research","doi-asserted-by":"publisher","award":["JPND2021-00694"],"award-info":[{"award-number":["JPND2021-00694"]}],"id":[{"id":"10.13039\/100013278","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017510","name":"UK Dementia Research Institute","doi-asserted-by":"publisher","award":["UKDRI-1003"],"award-info":[{"award-number":["UKDRI-1003"]}],"id":[{"id":"10.13039\/501100017510","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006306","name":"Sigrid Jus\u00e9liuksen S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","award":["339767"],"award-info":[{"award-number":["339767"]}],"id":[{"id":"10.13039\/501100006306","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006306","name":"Sigrid Jus\u00e9liuksen S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","award":["338182"],"award-info":[{"award-number":["338182"]}],"id":[{"id":"10.13039\/501100006306","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006306","name":"Sigrid Jus\u00e9liuksen S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","award":["355604"],"award-info":[{"award-number":["355604"]}],"id":[{"id":"10.13039\/501100006306","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005760","name":"University of Gothenburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005760","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurodegeneration"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>While the temporal profile of amyloid (A\u03b2) and tau cerebrospinal fluid (CSF) biomarkers along the Alzheimer\u2019s disease (AD) continuum is well-studied, chronological changes of CSF proteins reflecting other disease-relevant processes, denoted \u2018X\u2019 in the ATX(N) framework, remain poorly understood.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Using an untargeted mass spectrometric approach termed tandem mass tag (TMT), we quantified over 1500 CSF proteins across the AD continuum in three independent cohorts, finely staged by A\u03b2\/tau positron emission tomography (PET), fluid biomarkers, or brain biopsy. Weighted protein co-expression network analysis identified clusters of proteins robustly correlating in all three cohorts which sequentially changed with AD progression. Obtained protein clusters were correlated with fluid biomarker measurements (phosphorylated tau (p-tau) species including p-tau\n                      <jats:sub>181<\/jats:sub>\n                      , p-tau\n                      <jats:sub>217<\/jats:sub>\n                      , and p-tau\n                      <jats:sub>205<\/jats:sub>\n                      , as well as A\u03b2), A\u03b2\/tau PET imaging, and clinical parameters to discern disease-relevant clusters which were modelled across the AD continuum.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Neurodegeneration-related proteins (e.g\n                      <jats:italic>.<\/jats:italic>\n                      , 14\u20133-3 proteins, PPIA), derived from different brain cell types, strongly correlated with fluid as well as imaging biomarkers and increased early in the AD continuum. Among them, the proteins SMOC1 and CNN3 were highly associated with A\u03b2 pathology, while the 14\u20133-3 proteins YWHAZ and YWHAE as well as PPIA demonstrated a strong association with both A\u03b2 and tau pathology as indexed by PET. Endo-lysosomal proteins (e.g., HEXB, TPP1, SIAE) increased early in abundance alongside neurodegeneration-related proteins, and were followed by increases in metabolic proteins such as ALDOA, MDH1, and GOT1 at the mild cognitive impairment (MCI) stage. Finally, later AD stages were characterized by decreases in synaptic\/membrane proteins (e.g., NPTX2).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our study identified proxies of A\u03b2 and tau pathology, indexed by PET, (SMOC1, YWHAE, CNN3) and highlighted the dynamic fluctuations of the CSF proteome over the disease course, identifying candidate biomarkers for disease staging beyond A\u03b2 and tau.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13024-025-00841-0","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T16:58:39Z","timestamp":1746550719000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Cerebrospinal fluid proteome profiling across the Alzheimer\u2019s disease continuum: a step towards solving the equation for \u2018X\u2019"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-2298-220X","authenticated-orcid":false,"given":"Sophia","family":"Weiner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Sauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laia","family":"Montoliu-Gaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea L.","family":"Benedet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Ashton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Gonzalez-Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Simr\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nesrine","family":"Rahmouni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecile","family":"Tissot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Therriault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stijn","family":"Servaes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna","family":"Stevenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ville","family":"Leinonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuomas","family":"Rauramaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikko","family":"Hiltunen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Rosa-Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Gobom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,6]]},"reference":[{"issue":"10043","key":"841_CR1","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0140-6736(15)01124-1","volume":"388","author":"P Scheltens","year":"2016","unstructured":"Scheltens P, Blennow K, Breteler MMB, de Strooper B, Frisoni GB, Salloway S, et al. Alzheimer\u2019s disease. The Lancet. 2016;388(10043):505\u201317.","journal-title":"The Lancet"},{"issue":"1","key":"841_CR2","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13195-017-0283-5","volume":"9","author":"PS Aisen","year":"2017","unstructured":"Aisen PS, Cummings J, Jack CR, Morris JC, Sperling R, Fr\u00f6lich L, et al. On the path to 2025: understanding the Alzheimer\u2019s disease continuum. Alz Res Therapy. 2017;9(1):60.","journal-title":"Alz Res Therapy"},{"issue":"4","key":"841_CR3","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S1474-4422(13)70044-9","volume":"12","author":"VL Villemagne","year":"2013","unstructured":"Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid \u03b2 deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer\u2019s disease: a prospective cohort study. The Lancet Neurology. 2013;12(4):357\u201367.","journal-title":"The Lancet Neurology"},{"issue":"2","key":"841_CR4","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.cell.2019.09.001","volume":"179","author":"JM Long","year":"2019","unstructured":"Long JM, Holtzman DM. Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. Cell. 2019;179(2):312\u201339.","journal-title":"Cell"},{"issue":"s1","key":"841_CR5","doi-asserted-by":"publisher","first-page":"S123","DOI":"10.3233\/JAD-2012-129031","volume":"33","author":"JZ Wang","year":"2013","unstructured":"Wang JZ, Xia YY, Grundke-Iqbal I, Iqbal K. Abnormal Hyperphosphorylation of Tau: Sites, Regulation, and Molecular Mechanism of Neurofibrillary Degeneration. Journal of Alzheimer\u2019s Disease. 2013;33(s1):S123\u201339.","journal-title":"Journal of Alzheimer\u2019s Disease"},{"issue":"338","key":"841_CR6","doi-asserted-by":"publisher","first-page":"338ra66","DOI":"10.1126\/scitranslmed.aaf2362","volume":"8","author":"MR Brier","year":"2016","unstructured":"Brier MR, Gordon B, Friedrichsen K, McCarthy J, Stern A, Christensen J, et al. Tau and A\u03b2 imaging, CSF measures, and cognition in Alzheimer\u2019s disease. Science Translational Medicine. 2016;8(338):338ra66-338ra66.","journal-title":"Science Translational Medicine."},{"issue":"S165","key":"841_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1600-0404.1996.tb05866.x","volume":"94","author":"H Braak","year":"1996","unstructured":"Braak H, Braak E. Evolution of the neuropathology of Alzheimer\u2019s disease. Acta Neurol Scand. 1996;94(S165):3\u201312.","journal-title":"Acta Neurol Scand"},{"issue":"1","key":"841_CR8","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1053\/j.semnuclmed.2016.09.006","volume":"47","author":"VL Villemagne","year":"2017","unstructured":"Villemagne VL, Dor\u00e9 V, Bourgeat P, Burnham SC, Laws S, Salvado O, et al. A\u03b2-amyloid and Tau Imaging in Dementia. Semin Nucl Med. 2017;47(1):75\u201388.","journal-title":"Semin Nucl Med"},{"issue":"4","key":"841_CR9","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack","year":"2018","unstructured":"Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer\u2019s disease. Alzheimer\u2019s & Dementia. 2018;14(4):535\u201362.","journal-title":"Alzheimer\u2019s & Dementia"},{"issue":"4","key":"841_CR10","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.3233\/JAD-161088","volume":"57","author":"E T\u00f6nnies","year":"2017","unstructured":"T\u00f6nnies E, Trushina E. Oxidative Stress, Synaptic Dysfunction, and Alzheimer\u2019s Disease. Journal of Alzheimer\u2019s Disease. 2017;57(4):1105\u201321.","journal-title":"Journal of Alzheimer\u2019s Disease"},{"issue":"4","key":"841_CR11","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.bcp.2013.12.012","volume":"88","author":"SM de la Monte","year":"2014","unstructured":"de la Monte SM, Tong M. Brain metabolic dysfunction at the core of Alzheimer\u2019s disease. Biochem Pharmacol. 2014;88(4):548\u201359.","journal-title":"Biochem Pharmacol"},{"issue":"7","key":"841_CR12","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1096\/fj.201700359","volume":"31","author":"RA Nixon","year":"2017","unstructured":"Nixon RA. Amyloid precursor protein and endosomal\u2013lysosomal dysfunction in Alzheimer\u2019s disease: inseparable partners in a multifactorial disease. FASEB J. 2017;31(7):2729\u201343.","journal-title":"FASEB J"},{"key":"841_CR13","unstructured":"Jack Jr. CR, Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A, et al. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup. Alzheimer\u2019s & Dementia. [cited 2024 Aug 9];n\/a(n\/a). Available from: https:\/\/onlinelibrary.wiley.com\/doi\/abs\/10.1002\/alz.13859."},{"issue":"11","key":"841_CR14","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1038\/s43587-022-00300-1","volume":"2","author":"M del Campo","year":"2022","unstructured":"del Campo M, Peeters CFW, Johnson ECB, Vermunt L, Hok-A-Hin YS, van Nee M, et al. CSF proteome profiling across the Alzheimer\u2019s disease spectrum reflects the multifactorial nature of the disease and identifies specific biomarker panels. Nat Aging. 2022;2(11):1040\u201353.","journal-title":"Nat Aging"},{"issue":"5","key":"841_CR15","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/s41591-020-0815-6","volume":"26","author":"ECB Johnson","year":"2020","unstructured":"Johnson ECB, Dammer EB, Duong DM, Ping L, Zhou M, Yin L, et al. Large-scale proteomic analysis of Alzheimer\u2019s disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation. Nat Med. 2020;26(5):769\u201380.","journal-title":"Nat Med"},{"issue":"1","key":"841_CR16","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s43587-023-00550-7","volume":"4","author":"BM Tijms","year":"2024","unstructured":"Tijms BM, Vromen EM, Mjaavatten O, Holstege H, Reus LM, van der Lee S, et al. Cerebrospinal fluid proteomics in patients with Alzheimer\u2019s disease reveals five molecular subtypes with distinct genetic risk profiles. Nat Aging. 2024;4(1):33\u201347.","journal-title":"Nat Aging"},{"issue":"8","key":"841_CR17","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1038\/s41591-023-02476-4","volume":"29","author":"ECB Johnson","year":"2023","unstructured":"Johnson ECB, Bian S, Haque RU, Carter EK, Watson CM, Gordon BA, et al. Cerebrospinal fluid proteomics define the natural history of autosomal dominant Alzheimer\u2019s disease. Nat Med. 2023;29(8):1979\u201388.","journal-title":"Nat Med"},{"key":"841_CR18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41556-023-01344-0","volume":"26","author":"A Pichet Binette","year":"2024","unstructured":"Pichet Binette A, Gaiteri C, Wennstr\u00f6m M, Kumar A, Hristovska I, Spotorno N, et al. Proteomic changes in Alzheimer disease associated with progressive A\u03b2 plaque and tau tangle pathologies. Nat Neurosci. 2024;26:1\u201312.","journal-title":"Nat Neurosci"},{"issue":"3","key":"841_CR19","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimer\u2019s & Dementia. 2011;7(3):263\u20139.","journal-title":"Alzheimer\u2019s & Dementia"},{"issue":"7","key":"841_CR20","doi-asserted-by":"publisher","first-page":"e975","DOI":"10.1212\/WNL.0000000000011416","volume":"96","author":"J Therriault","year":"2021","unstructured":"Therriault J, Pascoal TA, Benedet AL, Tissot C, Savard M, Chamoun M, et al. Frequency of Biologically Defined Alzheimer Disease in Relation to Age, Sex, APOE \u03b54, and Cognitive Impairment. Neurology. 2021;96(7):e975\u201385.","journal-title":"Neurology"},{"issue":"4","key":"841_CR21","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF00308809","volume":"82","author":"H Braak","year":"1991","unstructured":"Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239\u201359.","journal-title":"Acta Neuropathol"},{"issue":"9","key":"841_CR22","doi-asserted-by":"publisher","first-page":"2818","DOI":"10.1093\/brain\/awaa180","volume":"143","author":"TA Pascoal","year":"2020","unstructured":"Pascoal TA, Therriault J, Benedet AL, Savard M, Lussier FZ, Chamoun M, et al. 18F-MK-6240 PET for early and late detection of neurofibrillary tangles. Brain. 2020;143(9):2818\u201330.","journal-title":"Brain"},{"issue":"1","key":"841_CR23","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13024-022-00586-0","volume":"17","author":"J Gobom","year":"2022","unstructured":"Gobom J, Benedet AL, Mattsson-Carlgren N, Montoliu-Gaya L, Schultz N, Ashton NJ, et al. Antibody-free measurement of cerebrospinal fluid tau phosphorylation across the Alzheimer\u2019s disease continuum. Mol Neurodegener. 2022;17(1):81.","journal-title":"Mol Neurodegener"},{"issue":"12","key":"841_CR24","doi-asserted-by":"publisher","first-page":"3776","DOI":"10.1093\/brain\/awaa325","volume":"143","author":"BM Tijms","year":"2020","unstructured":"Tijms BM, Gobom J, Reus L, Jansen I, Hong S, Dobricic V, et al. Pathophysiological subtypes of Alzheimer\u2019s disease based on cerebrospinal fluid proteomics. Brain. 2020;143(12):3776\u201392.","journal-title":"Brain"},{"issue":"10","key":"841_CR25","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13195-018-0396-5","volume":"6","author":"I Bos","year":"2018","unstructured":"Bos I, Vos S, Vandenberghe R, Scheltens P, Engelborghs S, Frisoni G, et al. The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics. Alzheimers Res Ther. 2018;6(10):64.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"841_CR26","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12987-023-00440-5","volume":"20","author":"S Weiner","year":"2023","unstructured":"Weiner S, Junkkari A, Sauer M, Luikku A, Rauramaa T, Kokkola T, et al. Novel cerebrospinal fluid biomarkers correlating with shunt responsiveness in patients with idiopathic normal pressure hydrocephalus. Fluids Barriers CNS. 2023;20(1):40.","journal-title":"Fluids Barriers CNS"},{"issue":"20","key":"841_CR27","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1212\/WNL.0b013e3182563bd0","volume":"78","author":"TT Sepp\u00e4l\u00e4","year":"2012","unstructured":"Sepp\u00e4l\u00e4 TT, Nerg O, Koivisto AM, Rummukainen J, Puli L, Zetterberg H, et al. CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings. Neurology. 2012;78(20):1568\u201375.","journal-title":"Neurology"},{"issue":"1","key":"841_CR28","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12987-019-0142-9","volume":"16","author":"A Junkkari","year":"2019","unstructured":"Junkkari A, Luikku AJ, Danner N, Jyrkk\u00e4nen HK, Rauramaa T, Korhonen VE, et al. The Kuopio idiopathic normal pressure hydrocephalus protocol: initial outcome of 175 patients. Fluids Barriers CNS. 2019;16(1):21.","journal-title":"Fluids Barriers CNS"},{"issue":"1","key":"841_CR29","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12014-022-09354-0","volume":"19","author":"S Weiner","year":"2022","unstructured":"Weiner S, Sauer M, Visser PJ, Tijms BM, Vorontsov E, Blennow K, et al. Optimized sample preparation and data analysis for TMT proteomic analysis of cerebrospinal fluid applied to the identification of Alzheimer\u2019s disease biomarkers. Clin Proteomics. 2022;19(1):13.","journal-title":"Clin Proteomics"},{"issue":"1","key":"841_CR30","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1186\/1471-2105-9-559","volume":"9","author":"P Langfelder","year":"2008","unstructured":"Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008;9(1):559.","journal-title":"BMC Bioinformatics"},{"issue":"W1","key":"841_CR31","doi-asserted-by":"publisher","first-page":"W207","DOI":"10.1093\/nar\/gkad347","volume":"51","author":"L Kolberg","year":"2023","unstructured":"Kolberg L, Raudvere U, Kuzmin I, Adler P, Vilo J, Peterson H. g:Profiler\u2014interoperable web service for functional enrichment analysis and gene identifier mapping (2023 update). Nucleic Acids Res. 2023;51(W1):W207\u201312.","journal-title":"Nucleic Acids Res"},{"issue":"7","key":"841_CR32","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"841_CR33","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s00401-023-02659-w","volume":"147","author":"J Lantero-Rodriguez","year":"2024","unstructured":"Lantero-Rodriguez J, Montoliu-Gaya L, Benedet AL, Vrillon A, Dumurgier J, Cognat E, et al. CSF p-tau205: a biomarker of tau pathology in Alzheimer\u2019s disease. Acta Neuropathol. 2024;147(1):12.","journal-title":"Acta Neuropathol"},{"issue":"S6","key":"841_CR34","doi-asserted-by":"publisher","first-page":"e062540","DOI":"10.1002\/alz.062540","volume":"18","author":"J Therriault","year":"2022","unstructured":"Therriault J, Pascoal TA, Lussier FZ, Tissot C, Bezgin G, Servaes S, et al. Biomarker modelling of Alzheimer\u2019s disease using in vivo Braak staging. Alzheimer\u2019s & Dementia. 2022;18(S6):e062540.","journal-title":"Alzheimer\u2019s & Dementia"},{"issue":"1","key":"841_CR35","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13195-020-00649-8","volume":"12","author":"CN Suire","year":"2020","unstructured":"Suire CN, Abdul-Hay SO, Sahara T, Kang D, Brizuela MK, Saftig P, et al. Cathepsin D regulates cerebral A\u03b242\/40 ratios via differential degradation of A\u03b242 and A\u03b240. Alz Res Therapy. 2020;12(1):80.","journal-title":"Alz Res Therapy"},{"issue":"2018","key":"841_CR36","first-page":"8407609","volume":"23","author":"J Zhang","year":"2018","unstructured":"Zhang J, Zhou Y. 14-3-3 Proteins in Glutamatergic Synapses. Neural Plast. 2018;23(2018):8407609.","journal-title":"Neural Plast"},{"issue":"1","key":"841_CR37","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13041-014-0088-4","volume":"7","author":"\u00c0 Bay\u00e9s","year":"2014","unstructured":"Bay\u00e9s \u00c0, Collins MO, Galtrey CM, Simonnet C, Roy M, Croning MD, et al. Human post-mortem synapse proteome integrity screening for proteomic studies of postsynaptic complexes. Mol Brain. 2014;7(1):88.","journal-title":"Mol Brain"},{"issue":"10","key":"841_CR38","doi-asserted-by":"publisher","first-page":"3358","DOI":"10.1021\/bi972274d","volume":"37","author":"CN Larsen","year":"1998","unstructured":"Larsen CN, Krantz BA, Wilkinson KD. Substrate Specificity of Deubiquitinating Enzymes: Ubiquitin C-Terminal Hydrolases. Biochemistry. 1998;37(10):3358\u201368.","journal-title":"Biochemistry"},{"issue":"2","key":"841_CR39","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S0092-8674(02)01012-7","volume":"111","author":"Y Liu","year":"2002","unstructured":"Liu Y, Fallon L, Lashuel HA, Liu Z, Lansbury PT. The UCH-L1 Gene Encodes Two Opposing Enzymatic Activities that Affect \u03b1-Synuclein Degradation and Parkinson\u2019s Disease Susceptibility. Cell. 2002;111(2):209\u201318.","journal-title":"Cell"},{"issue":"1","key":"841_CR40","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13024-023-00657-w","volume":"18","author":"I Pes\u00e4maa","year":"2023","unstructured":"Pes\u00e4maa I, M\u00fcller SA, Robinson S, Darcher A, Paquet D, Zetterberg H, et al. A microglial activity state biomarker panel differentiates FTD-granulin and Alzheimer\u2019s disease patients from controls. Mol Neurodegener. 2023;18(1):70.","journal-title":"Mol Neurodegener"},{"issue":"2","key":"841_CR41","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/jnc.15875","volume":"166","author":"V Matafora","year":"2023","unstructured":"Matafora V, Gorb A, Yang F, Noble W, Bachi A, Perez-Nievas BG, et al. Proteomics of the astrocyte secretome reveals changes in their response to soluble oligomeric A\u03b2. J Neurochem. 2023;166(2):346\u201366.","journal-title":"J Neurochem"},{"issue":"21","key":"841_CR42","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.3390\/cells12212512","volume":"12","author":"K Kirchner","year":"2023","unstructured":"Kirchner K, Garvert L, K\u00fchn L, Bonk S, Grabe HJ, Van der Auwera S. Detrimental Effects of ApoE \u03b54 on Blood-Brain Barrier Integrity and Their Potential Implications on the Pathogenesis of Alzheimer\u2019s Disease. Cells. 2023;12(21):2512.","journal-title":"Cells"},{"issue":"1","key":"841_CR43","volume":"13","author":"J Nilsson","year":"2021","unstructured":"Nilsson J, Gobom J, Sj\u00f6din S, Brinkmalm G, Ashton NJ, Svensson J, et al. Cerebrospinal fluid biomarker panel for synaptic dysfunction in Alzheimer\u2019s disease. Alzheimer\u2019s & Dementia: Diagnosis, Assessment & Disease Monitoring. 2021;13(1): e12179.","journal-title":"Alzheimer\u2019s & Dementia: Diagnosis, Assessment & Disease Monitoring"},{"issue":"43","key":"841_CR44","doi-asserted-by":"publisher","first-page":"eaaz9360","DOI":"10.1126\/sciadv.aaz9360","volume":"6","author":"L Higginbotham","year":"2020","unstructured":"Higginbotham L, Ping L, Dammer EB, Duong DM, Zhou M, Gearing M, et al. Integrated proteomics reveals brain-based cerebrospinal fluid biomarkers in asymptomatic and symptomatic Alzheimer\u2019s disease. Sci Adv. 2020;6(43):eaaz9360.","journal-title":"Sci Adv."},{"issue":"6","key":"841_CR45","doi-asserted-by":"publisher","first-page":"e9356","DOI":"10.15252\/msb.20199356","volume":"16","author":"JM Bader","year":"2020","unstructured":"Bader JM, Geyer PE, M\u00fcller JB, Strauss MT, Koch M, Leypoldt F, et al. Proteome profiling in cerebrospinal fluid reveals novel biomarkers of Alzheimer\u2019s disease. Mol Syst Biol. 2020;16(6):e9356.","journal-title":"Mol Syst Biol"},{"issue":"5","key":"841_CR46","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1002\/alz.12809","volume":"19","author":"J Nilsson","year":"2023","unstructured":"Nilsson J, Cousins KAQ, Gobom J, Portelius E, Chen-Plotkin A, Shaw LM, et al. Cerebrospinal fluid biomarker panel of synaptic dysfunction in Alzheimer\u2019s disease and other neurodegenerative disorders. Alzheimer\u2019s & Dementia. 2023;19(5):1775\u201384.","journal-title":"Alzheimer\u2019s & Dementia"},{"issue":"1","key":"841_CR47","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13024-015-0059-y","volume":"10","author":"WE Heywood","year":"2015","unstructured":"Heywood WE, Galimberti D, Bliss E, Sirka E, Paterson RW, Magdalinou NK, et al. Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay. Mol Neurodegeneration. 2015;10(1):64.","journal-title":"Mol Neurodegeneration"},{"issue":"4","key":"841_CR48","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1002\/acn3.745","volume":"6","author":"EL van der Ende","year":"2019","unstructured":"van der Ende EL, Meeter LH, Stingl C, van Rooij JGJ, Stoop MP, Nijholt DAT, et al. Novel CSF biomarkers in genetic frontotemporal dementia identified by proteomics. Annals of Clinical and Translational Neurology. 2019;6(4):698\u2013707.","journal-title":"Annals of Clinical and Translational Neurology"},{"issue":"4","key":"841_CR49","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s00401-004-0885-4","volume":"108","author":"T Umahara","year":"2004","unstructured":"Umahara T, Uchihara T, Tsuchiya K, Nakamura A, Iwamoto T, Ikeda K, et al. 14-3-3 proteins and zeta isoform containing neurofibrillary tangles in patients with Alzheimer\u2019s disease. Acta Neuropathol. 2004;108(4):279\u201386.","journal-title":"Acta Neuropathol"},{"issue":"86","key":"841_CR50","doi-asserted-by":"publisher","first-page":"101856","DOI":"10.1016\/j.arr.2023.101856","volume":"1","author":"Z Mi","year":"2023","unstructured":"Mi Z, Graham SH. Role of UCHL1 in the pathogenesis of neurodegenerative diseases and brain injury. Ageing Res Rev. 2023;1(86):101856.","journal-title":"Ageing Res Rev"},{"issue":"1","key":"841_CR51","doi-asserted-by":"publisher","first-page":"7298","DOI":"10.1038\/srep07298","volume":"4","author":"M Zhang","year":"2014","unstructured":"Zhang M, Cai F, Zhang S, Zhang S, Song W. Overexpression of ubiquitin carboxyl-terminal hydrolase L1 (UCHL1) delays Alzheimer\u2019s progression in vivo. Sci Rep. 2014;4(1):7298.","journal-title":"Sci Rep"},{"issue":"6","key":"841_CR52","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1111\/j.1471-4159.2011.07644.x","volume":"120","author":"M Zhang","year":"2012","unstructured":"Zhang M, Deng Y, Luo Y, Zhang S, Zou H, Cai F, et al. Control of BACE1 degradation and APP processing by ubiquitin carboxyl-terminal hydrolase L1. J Neurochem. 2012;120(6):1129\u201338.","journal-title":"J Neurochem"},{"key":"841_CR53","doi-asserted-by":"publisher","unstructured":"Meng F, Zhang X, Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI). Unveiling Potential Biomarkers in Cerebrospinal Fluid for Amyloid Pathological Positivity in Non-Demented Individuals. J Prev Alzheimers Dis. 2024 Jul 2 [cited 2024 Jul 31]; Available from: https:\/\/doi.org\/10.14283\/jpad.2024.129.","DOI":"10.14283\/jpad.2024.129"},{"issue":"1","key":"841_CR54","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s40478-022-01356-1","volume":"10","author":"E Drummond","year":"2022","unstructured":"Drummond E, Kavanagh T, Pires G, Marta-Ariza M, Kanshin E, Nayak S, et al. The amyloid plaque proteome in early onset Alzheimer\u2019s disease and Down syndrome. Acta neuropathol commun. 2022;10(1):53.","journal-title":"Acta neuropathol commun."},{"issue":"6220","key":"841_CR55","doi-asserted-by":"publisher","first-page":"1260419","DOI":"10.1126\/science.1260419","volume":"347","author":"M Uhl\u00e9n","year":"2015","unstructured":"Uhl\u00e9n M, Fagerberg L, Hallstr\u00f6m BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Proteomics. Tissue-based map of the human proteome. Science. 2015;347(6220):1260419.","journal-title":"Science."},{"key":"841_CR56","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1038\/s41593-024-01730-3","volume":"27","author":"AO Sasmita","year":"2024","unstructured":"Sasmita AO, Depp C, Nazarenko T, Sun T, Siems SB, Ong EC, et al. Oligodendrocytes produce amyloid-\u03b2 and contribute to plaque formation alongside neurons in Alzheimer\u2019s disease model mice. Nat Neurosci. 2024;27:1668\u201374. https:\/\/doi.org\/10.1038\/s41593-024-01730-3.","journal-title":"Nat Neurosci."},{"issue":"1","key":"841_CR57","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s13195-023-01311-9","volume":"15","author":"X Wang","year":"2023","unstructured":"Wang X, Liu L, Jiang X, Saredy J, Xi H, Cueto R, et al. Identification of methylation-regulated genes modulating microglial phagocytosis in hyperhomocysteinemia-exacerbated Alzheimer\u2019s disease. Alz Res Therapy. 2023;15(1):164.","journal-title":"Alz Res Therapy"},{"issue":"1","key":"841_CR58","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S0002-9440(10)64538-5","volume":"157","author":"AM Cataldo","year":"2000","unstructured":"Cataldo AM, Peterhoff CM, Troncoso JC, Gomez-Isla T, Hyman BT, Nixon RA. Endocytic Pathway Abnormalities Precede Amyloid \u03b2 Deposition in Sporadic Alzheimer\u2019s Disease and Down Syndrome: Differential Effects of APOE Genotype and Presenilin Mutations. Am J Pathol. 2000;157(1):277\u201386.","journal-title":"Am J Pathol"},{"issue":"16","key":"841_CR59","doi-asserted-by":"publisher","first-page":"6142","DOI":"10.1523\/JNEUROSCI.17-16-06142.1997","volume":"17","author":"AM Cataldo","year":"1997","unstructured":"Cataldo AM, Barnett JL, Pieroni C, Nixon RA. Increased Neuronal Endocytosis and Protease Delivery to Early Endosomes in Sporadic Alzheimer\u2019s Disease: Neuropathologic Evidence for a Mechanism of Increased \u03b2-Amyloidogenesis. J Neurosci. 1997;17(16):6142\u201351.","journal-title":"J Neurosci"},{"issue":"1","key":"841_CR60","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/mp.2014.135","volume":"20","author":"EM Knight","year":"2015","unstructured":"Knight EM, Williams HN, Stevens AC, Kim SH, Kottwitz JC, Morant AD, et al. Evidence that small molecule enhancement of \u03b2-hexosaminidase activity corrects the behavioral phenotype in Dutch APPE693Q mice through reduction of ganglioside-bound A\u03b2. Mol Psychiatry. 2015;20(1):109\u201317.","journal-title":"Mol Psychiatry"},{"issue":"24","key":"841_CR61","doi-asserted-by":"publisher","first-page":"10998","DOI":"10.1073\/pnas.88.24.10998","volume":"88","author":"AM Cataldo","year":"1991","unstructured":"Cataldo AM, Paskevich PA, Kominami E, Nixon RA. Lysosomal hydrolases of different classes are abnormally distributed in brains of patients with Alzheimer disease. Proc Natl Acad Sci. 1991;88(24):10998\u20131002.","journal-title":"Proc Natl Acad Sci"},{"issue":"6","key":"841_CR62","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1097\/00005072-199606000-00004","volume":"55","author":"AM Cataldo","year":"1996","unstructured":"Cataldo AM, Barnett JL, Mann DMA, Nixon RA. Colocalization of Lysosomal Hydrolase and \u03b2-Amyloid in Diffuse Plaques of the Cerebellum and Striatum in Alzheimer\u2019s Disease and Down\u2019s Syndrome. J Neuropathol Exp Neurol. 1996;55(6):704\u201315.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"1","key":"841_CR63","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13195-019-0533-9","volume":"11","author":"S Sj\u00f6din","year":"2019","unstructured":"Sj\u00f6din S, Brinkmalm G, \u00d6hrfelt A, Parnetti L, Paciotti S, Hansson O, et al. Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer\u2019s and Parkinson\u2019s disease. Alz Res Therapy. 2019;11(1):82.","journal-title":"Alz Res Therapy"},{"key":"841_CR64","unstructured":"Cruchaga C, Ali M, Shen Y, Do A, Wang L, Western D, et al. Multi-cohort cerebrospinal fluid proteomics identifies robust molecular signatures for asymptomatic and symptomatic Alzheimer\u2019s disease. Res Sq. 2024;rs.3.rs-3631708."},{"issue":"17","key":"841_CR65","doi-asserted-by":"publisher","first-page":"e1866","DOI":"10.1212\/WNL.0000000000201072","volume":"99","author":"A Rostamzadeh","year":"2022","unstructured":"Rostamzadeh A, Bohr L, Wagner M, Baethge C, Jessen F. Progression of Subjective Cognitive Decline to MCI or Dementia in Relation to Biomarkers for Alzheimer Disease. Neurology. 2022;99(17):e1866\u201374.","journal-title":"Neurology"},{"issue":"3","key":"841_CR66","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S1474-4422(19)30368-0","volume":"19","author":"F Jessen","year":"2020","unstructured":"Jessen F, Amariglio RE, Buckley RF, van der Flier WM, Han Y, Molinuevo JL, et al. The characterisation of subjective cognitive decline. The Lancet Neurology. 2020;19(3):271\u20138.","journal-title":"The Lancet Neurology"},{"issue":"6","key":"841_CR67","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s00401-014-1349-0","volume":"128","author":"JF Crary","year":"2014","unstructured":"Crary JF, Trojanowski JQ, Schneider JA, Abisambra JF, Abner EL, Alafuzoff I, et al. Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol. 2014;128(6):755\u201366.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"841_CR68","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/0924-977X(90)90017-5","volume":"1","author":"K Blennow","year":"1990","unstructured":"Blennow K, Wallin A, Fredman P, Gottfries CG, Karlsson I, Svennerholm L. Intrathecal synthesis of immunoglobulins in patients with Alzheimer\u2019s disease. Eur Neuropsychopharmacol. 1990;1(1):79\u201381.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"1","key":"841_CR69","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jns.2003.12.002","volume":"219","author":"S Seyfert","year":"2004","unstructured":"Seyfert S, Faulstich A, Marx P. What determines the CSF concentrations of albumin and plasma-derived IgG? J Neurol Sci. 2004;219(1):31\u20133.","journal-title":"J Neurol Sci"},{"issue":"3","key":"841_CR70","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/s41583-019-0132-6","volume":"20","author":"DA Butterfield","year":"2019","unstructured":"Butterfield DA, Halliwell B. Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease. Nat Rev Neurosci. 2019;20(3):148\u201360.","journal-title":"Nat Rev Neurosci"},{"issue":"4","key":"841_CR71","doi-asserted-by":"publisher","first-page":"778","DOI":"10.3390\/biomedicines10040778","volume":"10","author":"A Athanasaki","year":"2022","unstructured":"Athanasaki A, Melanis K, Tsantzali I, Stefanou MI, Ntymenou S, Paraskevas SG, et al. Type 2 Diabetes Mellitus as a Risk Factor for Alzheimer\u2019s Disease: Review and Meta-Analysis. Biomedicines. 2022;10(4):778.","journal-title":"Biomedicines"},{"issue":"2","key":"841_CR72","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/0006-8993(93)90699-N","volume":"602","author":"LA Adams","year":"1993","unstructured":"Adams LA, Ang LC, Munoz DG. Chromogranin A, a soluble synaptic vesicle protein, is found in cortical neurons other than previously defined peptidergic neurons in the human neocortex. Brain Res. 1993;602(2):336\u201341.","journal-title":"Brain Res"},{"key":"841_CR73","doi-asserted-by":"crossref","unstructured":"Chapman G, Shanmugalingam U, Smith PD. The Role of Neuronal Pentraxin 2 (NP2) in Regulating Glutamatergic Signaling and Neuropathology. Front Cell Neurosci. 2020 Jan 8 [cited 2024 Aug 1];13. Available from: https:\/\/www.frontiersin.org\/journals\/cellular-neuroscience\/articles\/10.3389\/fncel.2019.00575\/full.","DOI":"10.3389\/fncel.2019.00575"},{"issue":"9","key":"841_CR74","doi-asserted-by":"publisher","first-page":"mjad054","DOI":"10.1093\/jmcb\/mjad054","volume":"15","author":"I Paulussen","year":"2023","unstructured":"Paulussen I, Beckert H, Musial TF, Gschossmann LJ, Wolf J, Schmitt M, et al. SV2B defines a subpopulation of synaptic vesicles. Journal of Molecular Cell Biology. 2023;15(9):mjad054.","journal-title":"Journal of Molecular Cell Biology."},{"issue":"7","key":"841_CR75","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1093\/brain\/awae032","volume":"147","author":"J Nilsson","year":"2024","unstructured":"Nilsson J, Pichet Binette A, Palmqvist S, Brum WS, Janelidze S, Ashton NJ, et al. Cerebrospinal fluid biomarker panel for synaptic dysfunction in a broad spectrum of neurodegenerative diseases. Brain. 2024;147(7):2414\u201327.","journal-title":"Brain"},{"issue":"8","key":"841_CR76","doi-asserted-by":"publisher","first-page":"4454","DOI":"10.1007\/s00330-020-06825-6","volume":"30","author":"S Yamada","year":"2020","unstructured":"Yamada S, Ishikawa M, Ito H, Yamamoto K, Yamaguchi M, Oshima M, et al. Cerebrospinal fluid dynamics in idiopathic normal pressure hydrocephalus on four-dimensional flow imaging. Eur Radiol. 2020;30(8):4454\u201365.","journal-title":"Eur Radiol"}],"container-title":["Molecular Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-025-00841-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13024-025-00841-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-025-00841-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T05:04:17Z","timestamp":1746594257000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecularneurodegeneration.biomedcentral.com\/articles\/10.1186\/s13024-025-00841-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,6]]},"references-count":76,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["841"],"URL":"https:\/\/doi.org\/10.1186\/s13024-025-00841-0","relation":{},"ISSN":["1750-1326"],"issn-type":[{"value":"1750-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,6]]},"assertion":[{"value":"25 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The TRAID biomarker study was approved by the Montreal Neurological Institute PET working committee and the Douglas Mental Health University Institute Research Ethics Board. Written informed consent was obtained for all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"HZ has served at scientific advisory boards and\/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, LabCorp, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work).KB has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, BioArctic, Biogen, JOMDD\/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Ono Pharma, Pharmatrophix, Prothena, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper. The other authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"52"}}